Werbung
Werbung

VCYT

VCYT logo

Veracyte, Inc.

42.05
USD
Gesponsert
-1.51
-3.47%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

41.27

-0.78
-1.85%

VCYT Ergebnisberichte

Positives Überraschungsverhältnis

VCYT übertreffen die 28 der letzten 40Schätzungen.

70%

Nächster Bericht

Datum des nächsten Berichts
23. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$134.30M
/
$0.20
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+1.84%
/
-16.67%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+13.20%
/
+233.33%

Veracyte, Inc. earnings per share and revenue

On 04. Nov. 2025, VCYT reported earnings of 0.24 USD per share (EPS) for Q3 25, beating the estimate of 0.13 USD, resulting in a 78.97% surprise. Revenue reached 131.87 million, compared to an expected 127.65 million, with a 3.30% difference. The market reacted with a +27.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of 0.20 USD, with revenue projected to reach 134.30 million USD, implying an decrease of -16.67% EPS, and increase of 1.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
For Q3 2025, Veracyte, Inc. reported EPS of $0.24, beating estimates by 78.97%, and revenue of $131.87M, 3.3% above expectations.
The stock price moved up 27.46%, changed from $36.12 before the earnings release to $46.04 the day after.
The next earning report is scheduled for 23. Feb. 2026.
Based on 15 analysts, Veracyte, Inc. is expected to report EPS of $0.20 and revenue of $134.30M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung